Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]HRS-9057 in Healthy Participants
NCT07681479Phase 1Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-9057 in heart failure (HF), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Total radioactivity recovery and cumulative total radioactivity recovery in urine and feces, Percentage of HRS-9057 parent drug and its metabolites in plasma relative to the total radioactivity exposure in plasma and 6 more. Started Aug 2026; status: active, not recruiting.
02
Drugs
HRS-9057
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07681479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681479.